Document is current
Any future updates will be listed below
-
Authors
Thakkar, Astha https://orcid.org/0000-0001-7778-0752
Abreu, Michelly
Pradhan, Kith
Sica, R. Alejandro
Shastri, Aditi
Kornblum, Noah
Shah, Nishi
Mantzaris, Ioannis
Gritsman, Kira
Feldman, Eric
Elkind, Richard
Green-Lorenzen, Susan
Verma, Amit
Braunschweig, Ira
Goldfinger, Mendel https://orcid.org/0000-0002-4347-173X
- License Information
-
More Information
Article History
Received: 25 January 2022
Revised: 29 March 2022
Accepted: 30 March 2022
First Online: 28 April 2022
Competing interests
: AV has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly and is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene and received honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. KG has received research funding from ionctura, SA and ADC therapeutics. AS has received honorarium from GLG, Guidepoint, Onclive, consultation fee from Janssen Pharmaceuticals, advisory board fee from Rigel Pharmaceuticals, research funding from Kymera Therapeutics. AT, MA, KP, RAS, NK, NS, IM, EF, SGL, RE, IB and MG have nothing to disclose.
